GBA-Associated Synucleinopathies: Prime Candidates for Alpha-Synuclein Targeting Compounds
With disease-modifying compounds targeting alpha-synuclein available in clinical trials, patient stratification according to alpha-synuclein-specific enrichment strategies is a much-needed prerequisite. Such a scenario will be exemplified for GBA, one major genetic risk factor that is specifically a...
Main Author: | Kathrin Brockmann |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2020-09-01
|
Series: | Frontiers in Cell and Developmental Biology |
Subjects: | |
Online Access: | https://www.frontiersin.org/article/10.3389/fcell.2020.562522/full |
Similar Items
-
Glucocerebrosidase Mutations and Synucleinopathies. Potential Role of Sterylglucosides and Relevance of Studying Both GBA1 and GBA2 Genes
by: Rafael Franco, et al.
Published: (2018-06-01) -
Current Evidence for a Bidirectional Loop Between the Lysosome and Alpha-Synuclein Proteoforms
by: Norelle C. Wildburger, et al.
Published: (2020-11-01) -
GBA haploinsufficiency accelerates alpha synuclein pathology with altered lipid metabolism in a prodromal model of Parkinson’s disease
by: Ikuno, Masashi
Published: (2019) -
Motor Deficits in an Alpha-Synuclein Mouse Model of Parkinson's Disease are not Exacerbated by Gba1 Mutation
by: Fitzpatrick, Megan E.
Published: (2017) -
α-Synuclein accumulation and GBA deficiency due to L444P GBA mutation contributes to MPTP-induced parkinsonism
by: Seung Pil Yun, et al.
Published: (2018-01-01)